Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, EMEACLA | August 28, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date August 28, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,984 |
Reported balance
After 2026-08-28 transaction · row 1
1 source rowRow 1 · 2026-08-28 · Sale · Disposed 2,644 · Balance 17,984 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Aug 28, 2026 20:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,644 | $89.98 | $237,907.12 |
DisclosureSEC source: 0001225208-26-007377 · doc4.xml · nonDerivative · entry 1 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,984 Read SEC document |
| July 11, 2026 Filed Jul 13, 2026 20:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 109 | $92.21 | $10,050.89 |
DisclosureSEC source: 0001225208-26-006591 · doc4.xml · nonDerivative · entry 1 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,628 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 84 | $82.76 | $6,951.84 |
DisclosureSEC source: 0001225208-26-005042 · doc4.xml · nonDerivative · entry 2 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,737 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 6,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005042 · doc4.xml · derivative · entry 4 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,650 Underlying: Common Stock · 6,650 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 33,700 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005042 · doc4.xml · derivative · entry 3 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,700 Underlying: Common Stock · 33,700 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 6,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005042 · doc4.xml · nonDerivative · entry 1 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,821 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| July 11, 2025 Filed Jul 11, 2025 21:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 109 | $78.80 | $8,589.20 |
DisclosureSEC source: 0001225208-25-006643 · doc4.xml · nonDerivative · entry 1 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,171 Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004948 · doc4.xml · derivative · entry 3 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,200 Underlying: Common Stock · 6,200 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 31,600 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004948 · doc4.xml · derivative · entry 2 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,600 Underlying: Common Stock · 31,600 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004948 · doc4.xml · nonDerivative · entry 1 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,280 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.